Although the highly potent, selective, allosteric, oral, small molecule BRG1/BRM inhibitor FHD-286 elicited signs of clinical activity and safety as monotherapy in patients with metastatic uveal melanoma in the dose-escalation portion of a phase 1 trial (NCT04879017), further development in this indication will not be pursued, according to an announcement from Foghorn Therapeutics.
Clinical Trials
Clinical Trial Evaluates Smaller Surgical Margins for Stage 2 Melanoma Patients
Although most primary cutaneous melanomas are treated with surgical excision alone, current international guidelines vary on the optimal size for the surgical margins, which can range from 1 to 3 cm.
Navitoclax Plus Dabrafenib and Trametinib Shows Activity in BRAF-Mutant Melanoma
Combination treatment with dabrafenib, trametinib, and navitoclax has demonstrated activity in patients with BRAFV600-mutant, advanced melanoma, according to research presented at the ASCO Annual Meeting 2023.
Combination of mRNA-4157 With Pembrolizumab Improves Survival in Melanoma
In the phase 2 KEYNOTE-942 trial (NCT03897881), mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) led to a reduced risk of developing distant metastasis or death by approximately 65% vs with pembrolizumab alone as adjuvant therapy in patients with resected melanoma at high risk of recurrence, according to findings presented at the 2023 ASCO Annual Meeting.